A Link Between Air Pollution and Dementia Risk Is Supplied by New Data.

Published Date: 23 Apr 2023

According to the study, prolonged exposure to nitrogen dioxide, particulate matter PM2.5, and nitrogen oxide may raise the risk of dementia.

Read Full News

Latest News

How to Set a Biologic Strategy for Asthma, with Sara Assaf, MD Sara Assaf, MD

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Lungcast: Resilience and Sustainability: Preparing Healthcare for the Future with Elizabeth Cerceo, MD Albert Rizzo, MD, Elizabeth Cerceo, MD

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

Long-Term Data Support New Zopapogene Imadenovec Approval for RRP Victoria Johnson

New long-term data reveals that Papzimeos offers sustained relief for adults with recurrent respiratory papillomatosis, reducing the need for surgeries.

Nerandomilast Approval Breaks Decade-Long Dry Spell for IPF, With Toby Maher, MD, PhD Toby Maher, MD, PhD

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

Mucoactives Found to Have Little Benefit for Bronchiectasis Victoria Johnson

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

Todays Updates

NeuroVoices: Christina Briscoe, MD, on Improving Timely and Effective Care for Infantile Epileptic Spasm Syndrome Marco Meglio

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

Insight the Future of Anti-Tau Drug Development for Alzheimer Disease Marco Meglio

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Todays Updates

NeuroVoices: Christina Briscoe, MD, on Improving Timely and Effective Care for Infantile Epileptic Spasm Syndrome Marco Meglio

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

Insight the Future of Anti-Tau Drug Development for Alzheimer Disease Marco Meglio

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Latest News

Assaf shares insights into how to navigate patient profiles and treatment options to optimize severe asthma care with biologics.

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

New long-term data reveals that Papzimeos offers sustained relief for adults with recurrent respiratory papillomatosis, reducing the need for surgeries.

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

News All Time

Clinical and Patient Definitions of Acute COPD Exacerbation Recovery Differ Greatly Kevin Kunzmann

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

Dupilumab Lessens COPD Exacerbation Impact, with Nicola Hanania, MD, MS Nicola Hanania, MD, MS

Hanania discusses the pooled BOREAS and NOTUS post hoc data showing dupilumab protects lung function before and after COPD exacerbations.

Extended-Release Nalbuphine Improves Patient-Reported Refractory Chronic Cough Within 1 Week Imran Satia, MD, PhD

Imran Satia, MD, PhD, discusses promising phase 2A trial data showing quick and significant improvements in patients' perception of cough frequency and severity.

Baseline Type 2 Biomarkers Can Predict Asthma Remission with Dupilumab, with Mario Castro, MD, MPH Kevin Kunzmann

Castro discusses new data from CHEST 2025 showing the value of baseline blood eosinophils and FeNO in understanding potential dupilumab outcomes.

Dry Powder Treprostinil Tolerated Among Patients with PH-ILD, with Nicholas Kolaitis, MD Kevin Kunzmann

Kolaitis discussed interim findings from the ASCENT trial, which showed ability to increase treprostinil dosing while maintaining a safe and efficacious profile.

Aroxybutynin and Atomoxetine (AD109) Reduces Obstructive Sleep Apnea Burden in Phase 3 SynAIRgy Kevin Kunzmann

Late-breaking data at CHEST 2025 support the novel combination therapy, which may be submitted to the FDA in application for patients with OSA in coming months.

From Slowing Decline to Restoring Function: Taladegib’s Promise in IPF, With Toby Maher, MD, PhD Toby Maher, MD, PhD

Maher discussed taladegib's potential to improve FVC, rather than slow decline, in people with idiopathic pulmonary fibrosis.

Dupilumab Reduces Mucus Burden in Uncontrolled Asthma, with Njira Lugogo, MD Njira Lugogo, MD

Mucus plugs are an increasingly present issue in uncontrolled asthma. Lugogo discusses promising findings from VESTIGE that addresses them.

Dupilumab Bests Omalizumab in Airway Improvement for Patients with CRSwNP and Asthma Kevin Kunzmann

Data from the phase 4 head-to-head EVEREST trial further indicates dupilumab's benefit for type 2 inflammatory airway disease.

Defining the Future of Asthma Remission, With Linda Rogers, MD

Defining the Future of Asthma Remission, With Linda Rogers, MD

The Asthma and COPD Precision Medicine Era, with Nicola A. Hanania, MD, MS

The Asthma and COPD Precision Medicine Era, with Nicola A. Hanania, MD, MS

Personalized COPD Treatment: Lessons from Biologic Trials and Clinical Practice

Personalized COPD Treatment: Lessons from Biologic Trials and Clinical Practice

Early morning practices linked to less and lower-quality sleep in college athletes

A study using more than 27,000 sleep records of collegiate athletes provides the best evidence to date that early morning team practices take a toll on healthy sleep.

Dreaming of fewer running injuries? Start with better sleep

If you are among the 620 million people who lace up their running shoes on a regular basis, chances are that you're an early riser.

Daylight robbery? How London's skyscrapers deprive marginalized people of light

When you look at the promotional materials advertising luxury high-rise developments in London, it is obvious that the fantasy of living in the sky is fused by a desire for sunlight and "unobstructed" views of the city. Phrases ...

Chronic fatigue syndrome linked to high rates of dysfunctional breathing patterns

Chronic fatigue syndrome leaves patients exhausted and struggling with brain fog—and it typically gets worse after mental or physical exercise, a phenomenon called post-exertional malaise.

Recommended News For You

Medicaid expansion tied to smaller declines in early-stage cancer detection

Oncology Drug Shortages Persist, but Continue to Evolve

Pressing the Sleep button could have a positive impact on cognition.

Characterizing metastatic disease during adaptive therapy by using dynamic biomarkers and mathematical modeling.

What Dolph Lundgren's journey from terminal diagnosis to 'cancer free' can tell us about cancer care

CAR Natural Killer Cell Therapy Shows Promise in B-Cell Lymphomas

FDA-approved FGFR inhibitors show promise against rare and aggressive pediatric brain tumor

Recommended Articles For You

The Importance of Understanding Carboxyhemoglobin Levels in the Body: A Comprehensive Guide 

Management of Relapsed Synovial Sarcoma: Current Treatment Strategies and Emerging Therapies 

The Statistical Frontier of Hematology Oncology: Diagnostics, Therapies, and Future Horizons in Hematology Oncology 2025 

Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to new studies, some cancer patients can safely forego radiation therapy.

2.

A computer-aided diagnostic system for improved detection of breast cancer.

3.

Charles III, King of Kings, is Cancerous.

4.

Adult overdose deaths on the rise

5.

Preoperative MRI is useful for identifying additional disease in breast cancer patients with nodes positive.

1.

Exploring the Latest Advances in Hodgkin's Lymphoma Treatment

2.

Evolving Cancer Treatments: Innovations, Success Rates, and Mechanisms

3.

Ethics of Experimental Oncology: Case Study on Autonomy, Consent & Decision-Making

4.

PARP Inhibitors in Testicular Cancer: Tackling Cisplatin Resistance with Precision

5.

Unraveling the Mystery of Non-Caseating Granulomas: A Comprehensive Guide

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV

2.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part III

3.

EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion

4.

Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases

5.

Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot